Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/23/2015 01/26/2015 01/27/2015 01/28/2015 01/29/2015 Date
97.69(c) 99.51(c) 99.58(c) 97.25(c) 99.65(c) Last
1 687 975 1 277 109 968 236 1 289 639 1 029 012 Volume
+1.92% +1.86% +0.07% -2.34% +2.47% Change
More quotes
Company
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.The company operates its business through one segment, the biopharmaceutical development and commercialization segment.Its company's product portfolio is comprised of... 
Sector
Pharmaceuticals
Calendar
02/19Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 710 M
EBIT 2014 -120 M
Net income 2014 -153 M
Debt 2014 217 M
Yield 2014 -
Sales 2015 880 M
EBIT 2015 -258 M
Net income 2015 -313 M
Debt 2015 408 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 22,2x
EV / Sales 2015 18,1x
Capitalization 15 539 M
More Financials
Latest news on BIOMARIN PHARMACEUTICAL IN
01/23 BIOMARIN PHARMACEUTICAL : Entry into a Material Definitive Agreement, Other Even..
01/23 BioMarin Announces Underwriters' Full Exercise of Option to Purchase Addition..
01/22 BioMarin Announces Pricing of Public Offering of Common Stock
01/21 BioMarin Announces Public Offering of Common Stock
01/16 BIOMARIN PHARMACEUTICAL : Entry into a Material Definitive Agreement, Completion..
01/15 BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Comme..
01/13 BIOMARIN PHARMACEUTICAL : reports positive preliminary data from Phase I/II tria..
01/12 BioMarin Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BM..
More news
Sector news Generic Pharmaceuticals
04:51a Three months on, fruitless CEO search overshadows Sanofi
02:27aDJNOVO NORDISK A/S : 4Q Net Profit Beats Estimates
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
Plus d'actualités du secteur Generic Pharmaceuticals


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF